
ArriVent BioPharma, Inc.: financial statements
Price
$11.63
November 19, 2026Market cap $602M
What Ploutos Investor adds for ArriVent BioPharma
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 23% since Nov 9, 2026, when the 10-Q these figures come from was filed ($14.16 then, $10.90 on Nov 18, 2026). The figures date from before that move.10-Q
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Operating income
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Operating income | -$75M | -$94M | -$178M | |
| Net income | -$69M | -$80M | -$166M | |
| Earnings per share | -$32.38 | -$2.56 | -$4.32 | |
| Earnings per share, basic | -$32.38 | -$2.56 | -$4.32 |
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Dec 31, 2025Operating leases
$14.0K
Finance leases
–
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
The full analysis
What do ArriVent BioPharma's filings show?
These are ArriVent BioPharma's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much debt does AVBP have?
On December 31, 2025 ArriVent BioPharma had total assets of $333M, debt of – and shareholders' equity of $307M.
Where are the figures from?
From ArriVent BioPharma, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.